Ionis Pharmaceuticals, Inc. (IONS)
NASDAQ: IONS · Real-Time Price · USD
37.78
+0.01 (0.03%)
Nov 13, 2024, 4:00 PM EST - Market closed
Ionis Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 803.07 | 787.65 | 587.37 | 810.46 | 729.26 | 1,123 | Upgrade
|
| Revenue Growth (YoY) | 30.57% | 34.10% | -27.53% | 11.13% | -35.04% | 87.20% | Upgrade
|
| Cost of Revenue | 917.98 | 907.1 | 845.23 | 651.59 | 545.08 | 467.85 | Upgrade
|
| Gross Profit | -114.91 | -119.45 | -257.87 | 158.87 | 184.19 | 654.75 | Upgrade
|
| Selling, General & Admin | 230.41 | 212.62 | 150.3 | 186.35 | 354.32 | 286.64 | Upgrade
|
| Operating Expenses | 233.81 | 212.62 | 150.3 | 186.35 | 354.32 | 286.64 | Upgrade
|
| Operating Income | -348.72 | -332.07 | -408.16 | -27.48 | -170.13 | 368.11 | Upgrade
|
| Interest Expense | -90 | -81.46 | -8.12 | -9.35 | -9.51 | -12.44 | Upgrade
|
| Interest & Investment Income | 103.8 | 89.04 | 25.33 | 10.04 | 30.56 | 52.01 | Upgrade
|
| Other Non Operating Income (Expenses) | 1.43 | 0.87 | -7.27 | -1.13 | -0.06 | -0.69 | Upgrade
|
| EBT Excluding Unusual Items | -333.49 | -323.62 | -398.23 | -27.92 | -149.14 | 407 | Upgrade
|
| Gain (Loss) on Sale of Investments | -0.48 | -1.91 | -7.33 | 10.1 | 16.54 | 0.19 | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.16 | -0.16 | 149.6 | - | - | - | Upgrade
|
| Asset Writedown | -1.66 | -1.66 | -2.03 | -2.71 | -1.95 | -2.23 | Upgrade
|
| Other Unusual Items | -20 | -6.61 | - | -8.63 | - | -66.2 | Upgrade
|
| Pretax Income | -355.8 | -333.97 | -257.99 | -29.15 | -134.55 | 338.77 | Upgrade
|
| Income Tax Expense | 3.02 | 32.32 | 11.74 | -0.55 | 345.19 | 51.51 | Upgrade
|
| Earnings From Continuing Operations | -358.81 | -366.29 | -269.72 | -28.6 | -479.74 | 287.26 | Upgrade
|
| Minority Interest in Earnings | - | - | - | - | 35.48 | -9.12 | Upgrade
|
| Net Income | -358.81 | -366.29 | -269.72 | -28.6 | -444.26 | 278.14 | Upgrade
|
| Preferred Dividends & Other Adjustments | - | - | - | - | - | -2.42 | Upgrade
|
| Net Income to Common | -358.81 | -366.29 | -269.72 | -28.6 | -444.26 | 280.56 | Upgrade
|
| Net Income Growth | - | - | - | - | - | 1.61% | Upgrade
|
| Shares Outstanding (Basic) | 146 | 143 | 142 | 141 | 140 | 140 | Upgrade
|
| Shares Outstanding (Diluted) | 146 | 143 | 142 | 141 | 140 | 153 | Upgrade
|
| Shares Change (YoY) | 2.19% | 0.95% | 0.59% | 1.01% | -8.85% | 14.25% | Upgrade
|
| EPS (Basic) | -2.46 | -2.56 | -1.90 | -0.20 | -3.18 | 2.00 | Upgrade
|
| EPS (Diluted) | -2.46 | -2.56 | -1.90 | -0.20 | -3.18 | 1.90 | Upgrade
|
| EPS Growth | - | - | - | - | - | -8.23% | Upgrade
|
| Free Cash Flow | -370.91 | -331.32 | -290.09 | 18.84 | 0.77 | 314.72 | Upgrade
|
| Free Cash Flow Per Share | -2.54 | -2.31 | -2.05 | 0.13 | 0.01 | 2.05 | Upgrade
|
| Gross Margin | -14.31% | -15.17% | -43.90% | 19.60% | 25.26% | 58.32% | Upgrade
|
| Operating Margin | -43.42% | -42.16% | -69.49% | -3.39% | -23.33% | 32.79% | Upgrade
|
| Profit Margin | -44.68% | -46.50% | -45.92% | -3.53% | -60.92% | 24.99% | Upgrade
|
| Free Cash Flow Margin | -46.19% | -42.06% | -49.39% | 2.33% | 0.11% | 28.04% | Upgrade
|
| EBITDA | -336.27 | -319.22 | -391.42 | -9.64 | -154.71 | 382.56 | Upgrade
|
| EBITDA Margin | -41.87% | -40.53% | -66.64% | -1.19% | -21.21% | 34.08% | Upgrade
|
| D&A For EBITDA | 12.45 | 12.85 | 16.74 | 17.84 | 15.43 | 14.45 | Upgrade
|
| EBIT | -348.72 | -332.07 | -408.16 | -27.48 | -170.13 | 368.11 | Upgrade
|
| EBIT Margin | -43.42% | -42.16% | -69.49% | -3.39% | -23.33% | 32.79% | Upgrade
|
| Effective Tax Rate | - | - | - | - | - | 15.20% | Upgrade
|
| Revenue as Reported | 803.07 | 787.65 | 587.37 | 810.46 | 729.26 | 1,123 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.